Using prenatal blood samples to validate COVID-19 rapid serologic tests

Jackeline Alger
Universidad Nacional Autónoma de Honduras (UNAH)

Maria Luisa Cafferata
Instituto de Efectividad Clínica y Sanitaria

Tito Alvarado
3 Instituto de Enfermedades Infecciosas y Parasitología Antonio Vidal

Alvaro Ciganda
Unidad de Investigación Clínica y Epidemiológica

Arturo Corrales
Ingeniería Gerencial

Hans Desale
Tulane School of Public Health and Tropical Medicine

Amaud Drouin
Tulane School of Medicine

Dahlene Fusco
Tulane School of Medicine

Jorge Garcia
Hospital Escuela

Luz Gibbons
Instituto de Efectividad Clínica y Sanitaria

Emily Harville
Tulane School of Public Health and Tropical Medicine

Wendy Lopez
Hospital Escuela

Ivette Lorenzana
UNAH

Fausto Muñoz-Lara
Hospital Escuela

Elsa Palou
UNAH

Eduardo Retes
Universidad Católica de Honduras Nuestra Señora Reina de La Paz

Manuel Sierra
Short Report

Keywords: COVID-19, diagnostic testing, pregnancy, prenatal care, serologic tests

DOI: https://doi.org/10.21203/rs.3.rs-34571/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction

Background cross-reactivity with other coronaviruses may reduce the specificity of COVID-19 rapid serologic tests. Blood collected during prenatal care is a unique source of population-based samples appropriate for validation studies. We used stored 2018 serum samples from an existing pregnancy cohort study to evaluate the specificity of COVID-19 serologic rapid diagnostic tests.

Methods

We randomly selected 120 stored serum samples from pregnant women enrolled in a cohort in 2018, at least one year before the COVID-19 pandemic. We used stored serum to evaluate four lateral flow rapid diagnostic tests, following manufacturers’ instructions. Pictures were taken for all tests and read by two blinded trained evaluators.

Results

We evaluated 120, 80, 90, and 90 samples, respectively. Specificity for both IgM and IgG was 100% for the first two tests. The third test had a specificity of 98.9% for IgM and 94.4% for IgG. The fourth test had a specificity of 88.9% for IgM and 100% for IgG.

Discussion

COVID-19 serologic rapid tests are of variable specificity. Blood specimens from sentinel prenatal clinics provide an opportunity to validate serologic tests with population-based samples.

Significance

What is already known on this subject?

The validity of COVID-19 serologic rapid tests is not established, although they are becoming widely available. Sentinel prenatal clinics provide a unique opportunity to collect population-based blood samples for validation studies.

What this study adds.

We used stored serum samples collected in a sentinel prenatal clinic before the COVID-19 pandemic in Tegucigalpa, Honduras. We evaluated four rapid serologic tests and found specificities varying from 88.9% to 100%. The high number of false positives for some tests would make them less suitable for field studies.

Introduction
There is an urgent need to obtain serologic data for SARS-CoV-2, the virus causing COVID-19, for populations worldwide. The first COVID-19 case in Honduras was reported on March 10, 2020 (Gobierno de Honduras, 2020). Nine weeks later, the country has reported 2,646 COVID-19 cases, and a low testing rate of 572 tests per million inhabitants (Worldometer, 2020). Soon after the start of the COVID-19 pandemic in Honduras, the government independent group named Plataforma Todos Contra el COVID-19 (All Against COVID-19 Platform) was formed. One of the working aims of this group has been to guide and scale up the laboratory testing for confirmation of individual cases and for epidemiologic surveillance studies (“Plataforma Todos Contra el COVID-19,” 2020).

Rapid diagnostic tests (RDTs) could play a key role in serologic surveys, but their validity is often not well documented for COVID-19 tests (Sethuraman, Jeremiah, & Ryo, 2020). Blood routinely collected during prenatal care is a unique source of population-based samples which could be used to perform COVID-19 serologic studies (Buekens et al., 2020). Data from sentinel prenatal clinics are used to generate population-based estimates of infectious diseases seroprevalence. For example, HIV/AIDS seroprevalence is often estimated from prenatal care data (Eaton et al., 2014). Additionally, prenatal care offers a unique opportunity to collect data from a population of both asymptomatic and symptomatic women. Almost all women receive prenatal care to some extent, providing a better estimate of population seroprevalence than samples based on blood banks or volunteers.

The specificity of COVID-19 serologic tests has been questioned because of possible background cross-reactivity with other coronaviruses. This has been an issue for serological testing of SARS-CoV and MERS (Meyer, Drosten, & Müller, 2014). Specificity corresponds to the proportion of true negative among healthy subjects. We used stored serum samples collected before the pandemic from the Zika in Pregnancy in Honduras (ZIPH) cohort study to evaluate the specificity of COVID-19 serologic RDTs available for field studies in Honduras.

**Methods**

The current study leveraged stored serum samples from an existing prospective pregnancy cohort. The ZIPH study enrolls women at their first prenatal visit at the Alonso Suazo Health Center (Tegucigalpa, Honduras) and follows them up until delivery (Buekens et al., 2016). The health center is a large urban prenatal clinic with more than 1,100 new prenatal visits a year. We enrolled 3,991 women from July 2016 until March 2020. Data management is centralized at the Institute for Clinical Effectiveness and Health Policy (Instituto de Efectividad Clínica y Sanitaria, IECS), Buenos Aires, Argentina.

The Data Center selected at random 120 women who enrolled in 2018 and had authorized their blood samples to be stored for 10 years for additional studies. All samples were collected more than one year before the first case of COVID-19 was reported in Honduras. The Data Center prepared a list of study numbers (with control digits), which was emailed to Honduras where study labels were printed and pasted on data forms and on rapid tests immediately before use (Figure 1). Data were collected on paper
forms and entered in REDCap (Harris et al., 2009). Additionally, scans of each data form were taken and were sent (encrypted) to IECS. This system allows for a digital backup of all study data forms.

Four lateral flow RDT were obtained by the Plataforma Todos Contra el COVID-19 through the Honduran Sanitary Regulatory Agency (Agencia Regulatoria Sanitaria, ARSA,) or directly as a donation. We used the following lateral flow RDTs:

RDT#1: *Hightop COVID-19 IgM/IgG Ab Rapid Test Kit* (Qingdao Hantang Biological Technology Co., Ltd., Qingdao, China);

RDT#2: COVID-19 IgG/IgM Rapid Test Kit (Nantong Egens Biotechnology Co. Ltd., Nantong, China);

RDT#3: Orient Gene COVID-19 IgG/IgM Rapid Test (Zhejiang Orient Gene Biotech Co. Ltd, Huzhou, China).

RDT#4: Standard Q COVID-19 IgM/IgG Duo Test (SD Biosensor, Gyeonggi-do, Republic of Korea).

Laboratory procedures were performed at the Departamento de Laboratorio Clínico, Hospital Escuela, Tegucigalpa, Honduras. One aliquot of frozen serum was thawed and kept at 4°C for up to three days. Samples were brought to room temperature before testing. RDT packages were opened immediately before use. RDTs were performed following the manufacturers’ instructions. Rapid tests were read at 10 to 20 minutes according to the respective RDT instructions, and digital pictures were immediately taken using a cell phone camera. Pictures were taken under constant lighting conditions using two light sources. We used a 3x magnification to allow the picture to be taken from enough distance to avoid shadows. The pictures were uploaded to an encrypted cloud site and were immediately available to the Data Center. The pictures were then uploaded to a secure website and were read by two blinded trained evaluators and compared to the initial reading in the laboratory. Discrepancies were resolved by an independent blinded trained evaluator. This is similar to the approach we used earlier for Chagas RDTs (Buekens et al., 2013; Buekens et al., 2018).

This study was approved by Tulane University Institutional Review Board (893652; Amendment approval April 22, 2020), and by the Facultad de Ciencias Médicas, Universidad Nacional Autónoma de Honduras ethics committee (CEIB-079-2016; Amendment approval April 24, 2020). All women provided written informed consent at enrollment and authorized their blood samples to be stored for up to ten years.

**Results**

Table 1 shows the characteristics of the selected women enrolled in the ZIPH cohort.

| Table 1: Maternal Characteristics |
We tested 120 RDTs #1, 80 RDTs #2, and 90 RDTs #3 and #4 each. All tests had a clearly visible control band for all samples, except one for RDT #4. Pictures were taken for all tests (Figure 1). Table 2 shows that the specificity for both IgM and IgG was 100% for both RDT #1 and RDT #2. Specificity for RDT #3 was 98.9% for IgM and 94.4% for IgG. Specificity for RDT #4 was 88.9% for IgM and 100% for IgG.

|                          | IgM + | IgM Specificity % | IgG + | IgG Specificity % |
|--------------------------|-------|-------------------|-------|-------------------|
| RDT #1                   | 0/120 | 100               | 0/120 | 100               |
| RDT #2                   | 0/90  | 100               | 0/90  | 100               |
| RDT #3                   | 1/90  | 98.9              | 5/90  | 94.4              |
| RDT #4                   | 10/90 | 88.9              | 0/89  | 100               |

**Discussion**
Our results suggest that the COVID-19 serologic RDTs available in Honduras are of variable specificity when used in a general population. Specificity should have been 100% for all tests in these pre-COVID-19 samples. RDT #1 and #2 was 100% specific for both IgM and IgG, but specificity was as low as 88.9% for IgM for RDT #4 and 94.4% for IgG for RDT #3. None of the RDTs we tested are FDA approved, but all of them have a CE Mark for use in the European Union (Weissleder, Lee, Ko, & Pittet, 2020).

The specificities we found are comparable to the ones reported in the recent literature. A study of 10 serologic rapid tests found specificities varying from 91.6% to 100% among 108 blood donor plasma specimens collected in the United States before July 2018 ("COVID-19 Testing Project," 2020). A review of mostly unpublished data about 9 serologic RDTs found specificities of 98.7% to 100%, including RDT #1, for which reported specificities were of 96.0% for IgM and 97.5% for IgG (Zainol Rashid, Othman, Abdul Samat, Ali, & Wong, 2020). Hoffman et al (2020) evaluated RDT #3 and found higher specificities, 100% for IgM and 99.2% for IgG. A meta-analysis of regulatory data from serologic RDTs approved in Brazil found a pooled specificity of 97% for IgM and 98% for IgG (Castro et al., 2020). A study evaluating a RDT in China included 128 “clinical negative samples” and found one sample positive for IgG and 10 positive for IgM (Li et al., 2020). Of note, “clinical negative samples” in Li. et al. (2020) were from unconfirmed suspected COVID-19 cases, which could explain the high frequency of positive IgM. Another study of a COVID-19 serologic RDT found no positive among 26 healthy blood donors, with a specificity of 100% (Shen et al., 2020).

Data from SARS-CoV and MERS suggested that background cross-reactivity with other human coronaviruses was an issue (Meyer et al., 2014). However, this was mostly the case for tests detecting antibodies against the whole virus rather than the ones detecting antibodies against specific recombinant antigens. More than 90% of adults have been reported to have antibodies against the four human coronaviruses (Gorse, Patel, Vitale, & O’Connor, 2010). Coronavirus infection among children with influenza-like illness occurs in Central America as in other countries of the Americas (Taylor et al., 2017). An unexpected finding from a study from Vietnam showed that human coronavirus infection was less frequent among children with influenza-like illness when housing was overcrowded (Nguyen et al., 2016). The 2012 Honduras Demographic and Health Survey (DHS) shows that in Tegucigalpa, 38% of the households have > 4 people ("Encuesta Nacional de Salud y Demografía 2011-2012,") 2013). It is thus possible that circulation of other human coronaviruses is relatively low in our setting.

Rapid tests used for seroprevalence surveys need to be highly specific. The low specificity for IgG of RDT #3 is a concern, as it would falsely classify more than 5% of a healthy population as positive. We conclude that among those tested, COVID-19 serologic RDTs specificity varies from a low 88.9% to 100% in unaffected populations from Tegucigalpa, Honduras. If further studies confirm their sensitivity in that setting, highly specific tests would be the instrument of choice for serological surveys. The validity of all RDTs should be carefully evaluated, and blood specimens from sentinel prenatal clinics provide an opportunity to test them with population-based samples.

Declarations
Acknowledgements:

The Zika in Pregnancy in Honduras (ZIPH) study is partially funded by Vysnova Partners SC-2018-3045-TU. We thank the Honduras Agencia Regulatoria Sanitaria (ARSA) and to Diagnósticos LIDSA, Honduras, for providing the rapid tests. We thank Van Tong, MPH, for her support to the ZIPH study. We thank Fernando Althabe, MD, for his support. We thank Andrea Meyer for editing this manuscript.

Competing interests:

The authors declare no competing interests.

References

Buekens, P., Cafferata, M. L., Alger, J., Althabe, F., Belizán, J. M., Carlier, Y., et al. (2013). Congenital transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: study protocol. Reprod Health, 10, 55.

Buekens, P., Alger, J., Althabe, F., Bergel, E., Berrueta, A. M., Bustillo, C., et al. (2016). Zika virus infection in pregnant women in Honduras: study protocol. Reprod Health, 13(1), 82.

Buekens, P., Cafferata, M. L., Alger, J., Althabe, F., Belizán, J. M., Bustamante, N., et al. (2018). Congenital Transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: An Observational Prospective Study. Am J Trop Med Hyg, 98(2), 478-485.

Buekens, P., Alger, J., Bréart, G., Cafferata, M. L., Harville, E., & Tomasso, G. (2020). A call for action for COVID-19 surveillance and research during pregnancy. Lancet Glob Health, pii: S2214-109X(20)30206-0. doi: 10.1016/S2214-109X(20)30206-0. [Epub ahead of print].

Castro, R., Luz, P. M., Wakimoto, M. D., Veloso, V. G., Grinsztejn, B., & Perazzo, H. (2020). COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Braz J Infect Dis, pii: S1413-8670(20)30029-5. doi: 10.1016/j.bjid.2020.04.003. [Epub ahead of print].

COVID-19 Testing Project. (2020). https://covidtestingproject.org/. Accessed 5 May 2020.

Eaton, J. W., Rehle, T. M., Jooste, S., Nkambule, R., Kim, A. A., Mahy, M., et al. (2014). Recent HIV prevalence trends among pregnant women and all women in sub-Saharan Africa: implications for HIV estimates. AIDS, 28 Suppl 4, S507-514.

Encuesta Nacional de Salud y Demografía 2011-2012. (2013). Tegucigalpa, Honduras: Secretaría de Salud [Honduras], Instituto Nacional de Estadística (INE) e ICF International.

Gobierno de Honduras. (2020). Coronavirus COVID-19 en Honduras. https://covid19honduras.org/. Accessed 18 May 2020.
Gorse, G. J., Patel, G. B., Vitale, J. N., & O'Connor, T. Z. (2010). Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum. *Clin Vaccine Immunol, 17*(12), 1875-1880.

Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform, 42*(2), 377-381.

Li, Z., Yi, Y., Luo, X., Xiong, N., Liu, Y., Li, S., et al. (2020). Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J Med Virol*, doi: 10.1002/jmv.25727. [Epub ahead of print]

Meyer, B., Drosten, C., & Müller, M. A. (2014). Serological assays for emerging coronaviruses: challenges and pitfalls. *Virus Res, 194*, 175-183.

Nguyen, D. N. T., Mai, L. Q., Bryant, J. E., Hang, N. L. K., Hoa, L. N. M., Nadjm, B., et al. (2016). Epidemiology and etiology of influenza-like-illness in households in Vietnam; it's not all about the kids! *J Clin Virol, 82*, 126-132.

Plataforma Todos Contra el COVID-19. (2020). [http://www.bvs.hn/php/level.php?lang=es&component=59&item=63](http://www.bvs.hn/php/level.php?lang=es&component=59&item=63). Accessed 18 May 2020.

Sethuraman, N., Jeremiah, S. S., & Ryo, A. (2020). Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA*, doi: 10.1001/jama.2020.8259. [Epub ahead of print]

Shen, B., Zheng, Y., Zhang, X., Zhang, W., Wang, D., Jin, J., et al. (2020). Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG. *Am J Transl Res, 12*(4), 1348-1354.

Taylor, S., Lopez, P., Weckx, L., Borja-Tabora, C., Ulloa-Gutierrez, R., Lazcano-Ponce, E., et al. (2017). Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample. *J Infect, 74*(1), 29-41.

Weissleder, R., Lee, H., Ko, J., & Pittet, M. (2020). COVID-19 Diagnostics in Context. [https://csb.mgh.harvard.edu/covid](https://csb.mgh.harvard.edu/covid). Accessed 12 May 2020.

Worldometer. (2020). COVID-19 coronavirus pandemic. [https://www.worldometers.info/coronavirus/#countries](https://www.worldometers.info/coronavirus/#countries). Accessed 18 May 2020.

Zainol Rashid, Z., Othman, S. N., Abdul Samat, M. N., Ali, U. K., & Wong, K. K. (2020). Diagnostic performance of COVID-19 serology assays. *Malays J Pathol, 42*(1), 13-21.

**Figures**
Figure 1

Digital picture of COVID-19 rapid serological test (RDT#1) at 10-20 minutes with negative result (a) and RDT#3 with IgG (b) and RDT#4 with IgM (c) positive results.